

1 **A COMPLEX REGULATORY LANDSCAPE INVOLVED IN**
2 **THE DEVELOPMENT OF EXTERNAL GENITALS**

3
4
5
6
7 **Short title: *Hox* gene regulation during the development of genitals**

8
9
10
11
12
13 Ana Rita Amândio¹, Lucille Lopez-Delisle¹, Christopher Chase Bolt¹,
14 Bénédicte Mascrez² and Denis Duboule^{1,2,3,*}

15
16
17
18
19 ¹School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015
20 Lausanne, Switzerland. ²Department of Genetics and Evolution, University of Geneva, 30
21 quai Ernest Ansermet, 1211, Geneva, Switzerland. ³Collège de France, Paris, France

22
23
24
25 Key words: TADs, *Hox* clusters, chromatin conformation, CTCF, developmental enhancers,
26 loop extrusion model

27
28
29
30
31
32
33 *Corresponding author:
34 Denis Duboule
35 denis.duboule@epfl.ch
36 denis.duboule@unige.ch

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

ABSTRACT

In vertebrates, developmental genes are often controlled by large regulatory landscapes matching the dimensions of topologically associating domains (TADs). In various ontogenic contexts, the associated constitutive chromatin backbone is modified by fine-tuned specific variations in enhancer-enhancer and enhancer-promoter interaction profiles. In this work, we take one of the TADs flanking the *HoxD* gene cluster as a paradigm to address the question of how these complex regulatory architectures are formed and how they are de-constructed once their function has been achieved. We suggest that this TAD can be considered as a coherent functional unit in itself, with several regulatory sequences acting together to elicit a transcriptional response. With one notable exception, the deletion of each of these sequences in isolation did not produce any substantial modification in the global transcriptional outcome of the system, a result at odds with a conventional view of long-range enhancer function. Likewise, both the deletion and inversion of a supposedly critical CTCF site located in a region rich in such sequences did not affect transcription of the target gene. In the latter case, however, slight modifications were observed in interaction profiles *in vivo* in agreement with the loop extrusion model, despite no apparent functional consequences. We discuss these unexpected results by considering both conventional explanations and an alternative possibility whereby a rather unspecific accumulation of particular factors within the TAD backbone may have a global impact upon transcription.

63

64 INTRODUCTION

65

66 During mammalian development, the organization of body structures and their
67 morphogenesis require the accurate transcriptional regulation of the *Hox* gene family of
68 transcription factors. These proteins instruct progenitor cells, at different levels along the main
69 anterior to posterior (AP), about their developmental fates. In addition to this ancient role in
70 trunk patterning, subsets of the four *Hox* gene clusters were co-opted during evolution to
71 promote the development of secondary body axes such as the limbs and the external genitalia
72 (Dolle et al., 1991b). In the latter case, mice lacking both *Hoxa13* and *Hoxd13* function fail to
73 develop external genitalia due to a complete agenesis of the genital tubercle (GT) (Kondo et
74 al., 1997; Warot et al., 1997).

75 In the case of the *HoxD* cluster, the control of gene transcription in the emerging GT
76 involves *cis*-regulatory sequences located in a 700kb regulatory landscape positioned 5' to the
77 cluster, referred to as centromeric regulatory landscape (C-DOM). (Andrey et al., 2013;
78 Montavon et al., 2011; Spitz et al., 2003). This landscape matches one of the two topologically-
79 associating domains (TADs), which flank the gene cluster. The functional importance of the
80 C-DOM was confirmed by *in vivo* chromosome engineering studies. For example, when this
81 region was repositioned 3Mb away from *HoxD*, transcription of *Hoxd13* in the GT was almost
82 entirely abolished (Tschopp and Duboule, 2011) and subsequent deletions spanning various
83 parts of C-DOM supported this conclusion (Lonfat et al., 2014). Genetic and biochemical
84 analyses have shown that this entire regulatory landscape is shared between GT and digits, and
85 contains multiple enhancer sequences that are active in either both or in only one of these
86 developing structures (Gonzalez et al., 2007; Lonfat et al., 2014; Montavon et al., 2011).
87 Overall, it thus appears that within a large constitutive TAD structure, subtle yet specific
88 modifications of chromatin architecture are formed either in GT or in digit cells (Lonfat and
89 Duboule, 2015).

90 Unlike the opposite regulatory landscape (T-DOM), which includes a large variety of
91 enhancers with distinct specificities regulating the 'anterior' part of the *HoxD* cluster, the C-
92 DOM appears to be devoted to the control of the most posterior and distal terminal body
93 structures by regulating mostly *Hoxd13* either in digit cells or in the GT. The tropism of C-
94 DOM enhancers for *Hoxd13* results from the presence of a strong chromatin boundary between
95 this target gene and the rest of the cluster (Rodriguez-Carballo et al., 2017). Over the past years,
96 the importance of the C-DOM in controlling *Hoxd* genes expression has been clearly

97 demonstrated. However, both the dynamic behavior of such a regulatory landscape i.e. its
98 implementation and decommissioning, as well as the functional contribution of specific *cis*-
99 elements in these processes remained to be established in order to understand how an entire
100 TAD can be transcriptionally mobilized in different morphogenetic contexts to achieve similar
101 regulatory outcomes. A ‘specific’ view of the regulatory system would involve discriminative
102 factors, progressively building a tissue-specific chromatin context with a deterministic strategy.
103 Alternatively, a more generic process could be considered, where the accumulation of various
104 factors available in different tissues would elicit the same transcriptional response through
105 whichever chromatin configuration they would trigger.

106 In this work, we tackled these issues by studying both the *HoxD* locus chromatin
107 conformation dynamics during GT development, as well as the functional contribution of
108 specific *cis*-elements to *Hoxd* genes regulation. We observed that the gross chromatin
109 organization of C-DOM predates the appearance of the GT. As GT development progresses,
110 we observed a reduction in transcript levels correlating with a decrease in enhancer-promoter
111 chromatin loops within the C-DOM. This decrease occurred while maintaining a subset of
112 CTCF associated contacts, which are preserved independently from the transcriptional status
113 of the gene cluster. While both the deletion of the *Prox* enhancer and deletions of clusters of
114 enhancers severely affected *Hoxd* genes transcript levels, deletions of most other enhancers in
115 isolation had little (if any) effect on transcription in the GT. Moreover, the deletion of a
116 conserved CTCF site, the only one present in the central part of the regulatory landscape, did
117 not impact the transcriptional outcome, even though its inversion reallocated contacts in a
118 manner compatible with the loop extrusion model (Fudenberg et al., 2016; Rao et al., 2014;
119 Vian et al., 2018). These results point to a high resilience of the regulatory strategy at work in
120 this locus. They also suggest the existence in the same TAD of distinct mechanisms to control
121 target gene activation, either relying upon sequence specific enhancer-promoter interactions,
122 or involving less deterministic parameters and using the underlying chromatin structure.

123

124 **RESULTS**

125

126 ***Hox* genes and GT development**

127 To precisely assess *Hox* genes transcription during GT development, we initially
128 quantified their expression levels by using RNA-sequencing (RNA-seq). We analyzed datasets
129 from three different stages of GT embryonic development starting from embryonic day 12.5

130 (E12.5), E16.5 and E18.5. We observed that genes positioned in the 5' portion of both *HoxA*
131 (*Hoxa7* to *Hoxa13*) and *HoxD* (*Hoxd8* to *Hoxd13*) clusters were expressed at all developmental
132 stages (Figure 1A and Figure 1–figure supplement 1). Furthermore, with the exception of
133 *Hoxc11* and *Hoxc10*, only basal levels of mRNAs were scored for the *HoxC* and *HoxB* clusters
134 (Figure 1–figure supplement 1), consistent with previous observations (Hostikka and Capecchi,
135 1998; Montavon et al., 2008). Overall, we detected a general decrease in the amount of *Hox*
136 mRNAs during GT development, in particular for *Hoxd12* and *Hoxd13* (Figure 1A).

137 To try and define the full dynamics of *Hoxd* transcript accumulation during GT
138 development, we micro-dissected the cloaca region (CR) at E10.5, the major contributing
139 embryonic tissue to the emergence of the GT (Georgas et al., 2015), as well as genital buds at
140 E12.3, E13.5, E15.5, E16.5, E17.5 and E18.5. We performed RT-qPCR for *Hoxd13* and
141 detected transcripts in the CR at E10.5 (Figure 1B), followed by a significant increase in
142 transcript levels between the CR and the E12.5 GT ($p < 0.0001$). The mRNA levels then
143 remained constant between E12.5 and E13.5, whereas they were significantly reduced in E13.5
144 and E15.5 GTs ($p < 0.0001$). After E15.5, the transcript levels continued to decrease yet to a
145 lesser extent (between E15.5 and E18.5; $p = 0.0175$, Figure 1B), confirming the RNA-seq
146 results (Figure 1A).

147 We next compared chromatin accessibility and selected histone modifications in three
148 developmental stages to correlate with transcript levels. We used the CR at E10.5 (prior to GT
149 formation, low *Hoxd13* expression), GT at E13.5 (early GT development, high *Hoxd13*
150 expression) and GT at E17.5 (late GT development, low *Hoxd13* expression) and performed
151 ATAC-seq and ChIP-seq for both H3K27ac and H3K27me3 chromatin marks. At E10.5, prior
152 to GT formation, all *Hoxd* genes and *Evx2* were accessible as defined by ATAC-seq (Figure
153 1C). H3K27ac signals of moderate intensity were scored over the *Hoxd9* to *Evx2* interval as
154 well as peaks on the promoters of *Hoxd1*, *Hoxd3*, and *Hoxd4* (Figure 1C), indicating a
155 somewhat general activity of *Hoxd* genes in this region of the body axis. This was confirmed
156 by a low coverage in H3K27me3 marks, which were detected mostly over the *Evx2* gene
157 flanking the *Hox* cluster (Figure 1C, gray area).

158 At E13.5, in the growing genital bud, a different picture was observed with a whole
159 inactivation of the cluster from *Hoxd1* to *Hoxd10-11*, as indicated by a robust coverage of this
160 region by H3K27me3 marks and the disappearance of H3K27ac marks and ATAC-seq signals
161 (Figure 1D). In contrast, ATAC-seq peaks remained in the *Hoxd11* to *Evx2* region,
162 accompanied by a large increase in H3K27ac signals (Figure 1D) reflecting full transcription
163 of the latter genes. At this stage, a clear separation of the cluster into two distinct epigenetic

164 domains was scored, reminiscent of the situation described in distal forelimb buds (Andrey et
165 al., 2013). At E17.5, this clear dichotomy between epigenetic domains was still detected for
166 H3K27ac signals, though at a lower magnitude, but started to vanish when H3K27me3 marks
167 were considered, with their progressive spreading over the entire gene cluster. These data are
168 in agreement with the analysis of mRNA levels as observed by both RNA-seq and RT-qPCR.

169

170 **Implementation and decommissioning of a chromatin architecture**

171 *Hoxd* genes are regulated in the developing GT by long-range acting sequences
172 positioned within the flanking, centromeric-located TAD (C-DOM; Figure 2A). To assess the
173 dynamics of the TAD structure during bud development, we used circularized chromosome
174 conformation capture combined with high-throughput sequencing (4C-seq) to reveal the
175 physical chromatin interactions established between *Hoxd13* and the C-DOM, at various
176 developmental stages. *Hoxd13* was selected as a viewpoint since it is the highest expressed
177 *Hoxd* gene in this tissue and because its disruption leads to alterations in external genitals
178 (Dolle et al., 1993; Kondo et al., 1997; Warot et al., 1997). We micro-dissected CR at E10.5
179 and GTs at E12.5, E13.5, E15.5, and E17.5, and used forebrain at E12.5 as a control tissue
180 lacking *Hoxd* mRNA. As a baseline to our temporal series, we used a mouse embryonic stem
181 cells (mESC) dataset (Noordermeer et al., 2014) assuming that these cells somehow reflect the
182 ground-state 3D architecture of the gene cluster.

183 In mESC, contacts between *Hoxd13* and the C-DOM were mainly scored in the island
184 II and V regions. A large proportion of the interactions was scored in the cluster itself (Figure
185 2B, top, red lines) where they were likely driven by H3K27me3 marks (Vieux-Rochas et al.,
186 2015). This 3D architecture was altogether quite comparable to that found in forebrain cells
187 with discrete contacts established between *Hoxd13* and island II and V (Figure 2B, bottom, red
188 lines). These two profiles likely reflected the 3D chromatin state of C-DOM in the complete
189 absence of transcription. Upon transcriptional activation, however, frequencies of contacts with
190 the C-DOM increased and interactions between *Hoxd13* and previously characterized
191 enhancers (Prox, GT2) (Gonzalez et al., 2007; Lonfat et al., 2014) became visible (Figure 2B,
192 second track, blue lines). Quantification of these interactions revealed a 22% increase in overall
193 contacts over this regulatory region, when the CR at E10.5 was compared with ES cells (Figure
194 2B). This dataset showed a C-DOM specific chromatin architecture that is organized before
195 the emergence of the genital bud.

196 In subsequent stages of GT development (E12.5 or E13.5), contacts between various
197 enhancer regions and *Hoxd13* continued to increase to reach a maximum at E13.5 with an

198 additional 35% of overall interaction when compared to the CR sample (Figure 2B). As
199 development further progressed, contacts established between *Hoxd13* and C-DOM weakened.
200 From E13.5 to E17.5, there was a 28.1% decrease in interactions. At the latter stage the profile
201 observed was comparable to either forebrain cells or the mESC profiles, with a loss of contacts
202 with specific enhancers (Prox and GT2; Figure 2B). We quantified the percent of fragments
203 covering each regulatory island by using mESC as a reference (Figure 2–figure supplement
204 2A). The relative frequency of contacts with island II and island V remained fairly constant in
205 all samples analyzed. In contrast, the contacts between *Hoxd13* and either Prox or GT2
206 dramatically increased from the mESC to the E13.5 GT samples. The decrease in contacts
207 observed between E13.5 to E17.5 GTs correlated with a decrease in *Hoxd13* transcript levels.
208 Fetal forebrain cells, which do not express any *Hoxd* genes, showed the lowest values of
209 interactions between *Hoxd13* and either Prox or GT2 (Figure 2–figure supplement 2A).

210 To validate these results, we selected both the GT2 region, which displayed important
211 changes in interaction frequencies with *Hoxd13* during GT development, and the island V
212 region which showed more constitutive contacts, as viewpoints in 4C-seq experiments. We
213 used 4C-seq libraries for E12.5, E13.5, E15.5, and E17.5 GT cells and for E12.5 forebrain cells
214 as negative control. We confirmed that the interactions between GT2 and the *Hoxd13* region
215 substantially decreased from E13.5 to E17.5, whereas contact frequencies between island V
216 and *Hoxd13* was essentially stable, regardless of the stage and tissue analyzed (Figure 2–figure
217 supplement 2B). Therefore, as transcription decreased, some contacts established with C-DOM
218 were lost whereas others were maintained (island II and island V), indicating that at the time
219 transcription is switched off, C-DOM goes back to the pre-organized chromatin backbone that
220 characterizes tissues or cells that do not express any *Hox* genes. Of note, the constitutive contact
221 regions include binding sites occupied by CTCF (see below), a protein known to facilitate
222 enhancer-promoter contacts by DNA-looping (see (Ong and Corces, 2014)).

223

224 **Dissecting the regulatory potential of the C-DOM TAD**

225 We next explored the functional dynamics of C-DOM during GT development. A
226 detailed analysis of our CR ATAC-seq and ChIP-seq datasets revealed several accessible
227 chromatin sites, some of which correspond to previously identified GT enhancers such as GT2
228 (Lonfat et al., 2014) (Figure 3A, black arrow). Noteworthy, the GT and limb enhancer sequence
229 Prox was not yet accessible at this stage (Figure 3A, red arrow). At E13.5, when C-DOM is
230 fully active, both chromatin accessibility peaks and H3K27ac marks were scored over
231 previously characterized enhancers within this region, including Prox and GT2 (Figure 3A).

232 As development progressed, in E17.5 GT, H3K27ac marks were lost in C-DOM (Figure 3A)
233 correlating with the loss of both *Hoxd* transcripts and chromatin interactions (see above).

234 To evaluate the functional importance of sub-regions of C-DOM for the transcriptional
235 control of *Hoxd* genes during GT development, we used a series of partial deletions, in
236 particular the *Del(rel1-rel5)*, *Del(rel5-SB)* and the *Del(SB-Atf2)* alleles (Figure 3A, bottom) as
237 well as the *Del(IV-SB)* allele corresponding to a deletion between island IV and SB (Figure 3A,
238 bottom). The latter allele, a 154 kb large deficiency, removed half of the regulatory region
239 between the *rel5* and *SB* breakpoints and contained three GT regulatory regions, E1, III E and
240 IVE (see below). We analyzed the effect of each of these four deletions on *Hoxd* genes
241 transcription by RT-qPCR at E12.5.

242 In the *Del(rel1-rel5)* allele, one-third of C-DOM is removed, including two digit and/or
243 GT enhancers (GCR and Prox) (Gonzalez et al., 2007; Spitz et al., 2003) (Figure 3A, bottom).
244 In these mutant mice, a 47% reduction in *Hoxd13* mRNA levels was scored in the GT
245 ($p=0.0005$), whereas, *Hoxd12*, *Hoxd11*, and *Hoxd10* were less affected (Figure 3B). The
246 *Del(rel5-SB)* allele is a 300kb large deletion of C-DOM including the GT2, and island III, IV
247 and V regulatory sequences. Mice carrying this deletion displayed a greater effect on the
248 steady-state level *Hoxd13* mRNAs, which was reduced by 76% ($p<0.0001$). Again, *Hoxd12*,
249 *Hoxd11* and *Hoxd10* were also affected, yet to a lower extent (Figure 3C). We next analyzed
250 the *Del(IV-SB)* allele and noticed a 38% decrease in the amount of *Hoxd13* mRNAs ($p=0.0066$),
251 yet no significant effect was detected for any other genes (Figure 3D). Finally, we looked at
252 the *Del(SB-Atf2)* allele where the most centromeric part of the TAD had been deleted. In these
253 mutant mice, we observed a slight but significant upregulation of *Hoxd13* mRNA levels
254 ($p=0.003$) in the GT, whereas other genes were not affected (Figure 3E). Taken together, these
255 results indicated that several non-overlapping regions located within C-DOM are required for
256 the transcriptional activation of *Hoxd13* in the developing GT.

257

258 **Deletion of the Prox enhancer sequence**

259 Within the different DNA intervals delimited by our large deletions, we assessed the
260 contribution of single regulatory elements to the control of *Hoxd13* transcription. We applied
261 CRISPR/Cas9 genome editing to fertilized eggs and generated a series of alleles where these
262 elements were either deleted or inverted. We initially focused on the region between the *rel1*
263 and *rel5* breakpoints (Figure 3A, bottom). In this genomic interval the limb- and GT-specific
264 Prox enhancer (Figure 4B) accounted for the majority of chromatin interactions with *Hoxd13*

265 and presented strong coverage by H3K27ac marks in the GT (Figure 3A). We generated the
266 *Del(Prox)* allele, a micro-deletion of the Prox sequence (Figure 4A), and observed a 36%
267 decrease in the expression of *Hoxd13* by qPCR in E12.5 GTs ($p=0.006$) (Figure 4C). This
268 severe impact seemed to be exclusively quantitative, as the *Hoxd13* expression pattern detected
269 by whole mount *in situ* hybridization (WISH) remained unchanged (Figure 4D). This result
270 indicated that the Prox enhancer accounts for more than a third of the *Hoxd13* transcriptional
271 efficiency and is thus a major contributor to this regulation in GT.

272 We then looked at whether this effect was ‘enhancer-autonomous’ or if it involved a
273 significant reorganization of the entire C-DOM regulatory landscape by performing ATAC-
274 seq and 4C-seq in both control and *Del(Prox)* mutant E13.5 GTs (Figure 4E-F). The ATAC-
275 seq profiles revealed no obvious change in chromatin accessibility throughout the C-DOM
276 after the deletion of Prox (Figure 4E). Likewise, when we examined the potential importance
277 of Prox in building the C-DOM interaction landscape by 4C-seq using *Hoxd13* as a viewpoint,
278 we only noticed minor alterations in the frequency of contacts between *Hoxd13* and discrete
279 *cis*-regulatory elements (Figure 4F). We thus concluded that the Prox enhancer, while of
280 critical importance for regulating *Hoxd13*, does not actively contribute to the general
281 architectural organization of the locus.

282

283 **Identification of GT-specific enhancers**

284 In order to identify other elements acting in GT, we then focused on the genomic
285 interval positioned between the *SB* and the *rel5* breakpoints (Figure 5A), since this region
286 accounted for 76% of *Hoxd13* expression in the incipient bud (see Figure 3C). Based on
287 ATAC-seq, H3K27ac ChIP-seq, 4C-seq datasets and on DNA sequence conservation, we
288 selected five sub-regions of approximately 30kb in size and tested them for enhancer activity
289 in transgenic assays (Figure 5B, C). Each region was cloned upstream of a *LacZ* reporter gene
290 driven by a minimal *beta-globin* promoter and integrated at random positions in the mouse
291 genome.

292 X-gal staining of E13.5 transgenic embryos revealed enhancer activity in the GT for
293 the IIIIE and IVE sequences (Figure 5C), in cellular territories included within the wider
294 expression domain of *Hoxd13* in this tissue. These two sequences showed complementary
295 specificities, with IIIIE active in dorsal GT cells, whereas the IVE sequence strongly labelled
296 the ventral half of the GT (Figure 5C). Embryos injected with the E1 sequence showed a weak
297 only signal on the GT (Figure 5C) and no staining was scored either when using the VE, or the

298 E2 sequences (Figure 5C), despite their promising chromatin signatures. Of particular interest,
299 the VE region includes a CTCF binding site. These elements are involved in facilitating
300 enhancer-promoter contact by DNA-looping (e.g. (Long et al., 2016) and this particular CTCF
301 binding sequence is the only strongly occupied site present in the ca 550kb-region between
302 *Evx2* and island II.

303 Therefore, out of the five regions tested, only E1, IIIIE, and IVE showed some activity
304 in the developing GT. We also re-investigated the activity of the GT2 sequence in transgenic
305 embryos and scored a strong staining throughout the bud (Figure 5C). These experiments
306 highlighted the regulatory complexity of the C-DOM, with individual enhancer elements
307 displaying distinct and complementary patterns of activity (e.g., IIIIE and IVE), while others
308 show largely overlapping domains of expression (e.g., GT2).

309

310 **Serial deletions of single *cis*-regulatory elements**

311 To further evaluate the regulatory potential of these DNA sequences, we generated
312 deletion alleles for all suspected enhancers located between the *rel5* and *SB* breakpoints. When
313 deleted, this region had the largest impact upon *Hoxd13* transcription (Figure 3C). Therefore,
314 independent mouse strains were produced carrying either a *Del(GT2)*, *Del(IV)* or *Del(IIIIE)*
315 allele. In addition, to assess the importance of bound CTCF proteins within island V, we both
316 deleted and inverted this region (*Del(V)* and *Inv(V)*, respectively) (Figure 6A). As a read out,
317 we quantified *Hoxd13* mRNA levels by RT-qPCR and examined the transcripts distribution by
318 WISH. Unexpectedly, we did not detect any significant difference, either in transcript levels or
319 in their spatial patterns, in any of the *Del(GT2)*, *Del(IV)*, *Del(IIIIE)*, *Del(V)* and *Inv(V)* alleles
320 (Figure 6B, C). Unlike the Prox sequence analyzed above, these results suggest that none of
321 these sequences is in itself functionally important enough to elicit a visible transcriptional
322 effect upon the main target gene, at least in the GT and at the developmental stage considered.

323 The lack of visible effect of the *Del(GT2)* allele was particularly surprising, for this
324 sequence displayed a strong, highly specific and continuous staining in the GT in transgenic
325 embryos and also because of the robust transcriptional down-regulation obtained when using a
326 larger deletion including it. Consequently, we performed both 4C-seq and ATAC-seq in
327 *Del(GT2)* homozygous GT at E13.5 to assess whether this deletion would at least impact the
328 functional organization of the regulatory landscape (Figure 6–figure supplement 3). Except for
329 the loss of a single accessibility peak located between GT2 and CsB in the *Del(GT2)* mutant
330 allele (Figure 6–figure supplement 3A, black arrows), the distribution of accessible DNA
331 sequences over C-DOM appeared to be independent from the GT2 element (Figure 6–figure

332 supplement 3). This absence of global impact of the GT2 deletion was confirmed when using
333 a viewpoint on *Hoxd13* to evaluate by 4C-seq, potential reallocations of contacts in the mutant
334 allele. There again, no salient change in the chromatin organization of C-DOM was observed
335 (Figure 6–figure supplement 3B), further indicating that the deletion of GT2 in isolation had
336 essentially no effect on the global architecture of the C-DOM landscape.

337 This absence of visible impact after deletion of a strong and specific enhancer can be
338 due to a variety of reasons (see the discussion). Amongst them, the possibility that the
339 functional contribution of GT2 is required at a particular stage of GT development, which was
340 not considered in our analyses. To explore this possibility, we used RT qPCR to measure the
341 *Hoxd13* mRNA level in the CR at E10.5, a developmental stage where this enhancer is already
342 accessible, as seen in our ATAC-seq dataset (Figure 6–figure supplement 3C, black arrow),
343 and capable of triggering *lacZ* transcription (Lonfat, 2013). At this early stage, we observed a
344 slight (27%), but significant ($p=0.0152$) decrease in the expression of *Hoxd13* (Figure 6–figure
345 supplement 3D), suggesting that GT2 alone may have a role in controlling *Hoxd13* expression
346 prior to GT formation.

347

348 **CTCF and C-DOM chromatin organization**

349 Amongst the various sequences isolated in C-DOM, island V was shown to interact
350 with *Hoxd13* in all tissues and developmental stages analyzed thus far. We used our *Del(V)*
351 and *Inv(V)* alleles to evaluate the importance of this element in ensuring proper 3D-chromatin
352 organization at the *HoxD* locus. We first defined the CTCF binding profile in wildtype and
353 mutant E13.5 GTs, by using both ChIP-seq and Cut & Run (CnR). In the wildtype locus, our
354 Chip-seq results showed several CTCF binding sites in the centromeric part of C-DOM,
355 primarily between island II and *Atf2* and matching with other islands and 4C-seq peaks, close
356 to the centromeric TAD boundary (Figure 7A). Of note, island V was the only region between
357 *Evx2* and island II (approximately 550kb in linear distance) where a clear binding of this protein
358 was detected (Figure 7A, arrow). A close examination of this element revealed a major CTCF
359 binding site oriented towards the cluster and a weaker site observed nearby. In the *HoxD* cluster,
360 the distribution of bound CTCF was as for limb buds cells (Lonfat, 2013), with a series of
361 strong sites at its 5' extremity flanking *Hoxd13* and orientated towards C-DOM (Figure 7A).

362 We first verified the CTCF binding profiles in the two island V mutant alleles. As
363 expected, the *Del(V)* allele showed a complete loss of CTCF associated with island V (Figure
364 7A). In contrast, when we analyzed CTCF occupancy in the *Inv(V)* allele in GT at E13.5, a

365 strong CTCF binding to the major peak was detected, indicating that the inversion of the site
366 did not affect its binding capacity (Figure 7A). We next looked at the potential impact of either
367 deleting or inverting this CTCF site on the remaining regulatory elements by performing
368 ATAC-seq in wildtype, *Del(V)*, and *Inv(V)* homozygous GT at E13.5. In mutant *Del(V)* GT
369 cells, with the exception of the deleted region, we did not observe any change in the ATAC-
370 seq profile (Figure 7-figure supplement 4A) when compared to control GT cells. Minor
371 changes were not reproduced in replicates and were likely due to individual variation (Figure
372 7-figure supplement 4A). In the mutant *Inv(V)* GT cells, we observed the loss of one ATAC-
373 seq peak located between the GT2 and CsB sequences (Figure 7-figure supplement 4A, black
374 arrow), similar to what was scored in the *Del(GT2)* allele. Therefore, neither the deletion nor
375 the inversion of this centrally-located CTCF site had any substantial effect on the accessibility
376 of the remaining regulatory elements, corroborating the RT-qPCR results where expression of
377 *Hoxd13* was unchanged in these two alleles (Figure 6).

378 The position and orientation of this CTCF site suggested that it may play a role in
379 helping the central part of the C-DOM, rich in potential GT-specific elements, to reach *Hoxd13*
380 through the formation of a large loop. We thus performed 4C-seq by using the *Del(V)* and *Inv(V)*
381 mutant alleles on GT cells at E13.5 to investigate whether either the absence or the inversion
382 of the CTCF site would affect the interaction landscape within C-DOM. When *Hoxd13* was
383 taken as a viewpoint for the *Del(V)* allele, the global interaction profile between *Hoxd13* and
384 C-DOM was virtually identical to control (Figure 7B). We confirmed this result by using a
385 viewpoint positioned on island IV, at the vicinity of island V. Only a slight reduction in the
386 frequency of contacts between island IV and *Hoxd13* was scored (Figure 7B, black arrow).
387 Therefore, island V and its associated CTCF site have a marginal importance in maintaining
388 the global chromatin structure of this regulatory landscape.

389 The majority of CTCF mediated chromatin loops are established between sites
390 displaying opposite and convergent orientations (i.e. with CTCF motifs pointing toward each
391 other) (de Wit et al., 2015; Rao et al., 2014; Vietri Rudan et al., 2015). Because our *Inv(V)*
392 allele modified the orientation of this centrally-positioned CTCF site, we analyzed the impact
393 of this inversion upon chromatin conformation. Qualitative analysis of the interaction profile
394 generated using *Hoxd13* as a viewpoint revealed a slight disruption in the contacts between
395 *Hoxd13* and island V (Figure 7C, red arrow). We validated this result by doing the reverse
396 experiment and using a viewpoint on island V. In this set up, we observed a reduction in the
397 overall frequency of interactions in the region between island V and *Hoxd13* thus confirming
398 the previous result (Figure 7C and Figure 7-figure supplement 4B). Noteworthy, we observed

399 an increase in the interaction frequency in the region centromeric to island V up to island II
400 and island C, i.e. with the next CTCF sites displaying opposite and convergent orientations in
401 the mutant configuration (Figure 7C and Figure 7-figure supplement 4B). When we used island
402 IV as a viewpoint, we also observed a reduction in contacts with *Hoxd13* (Figure 7C, arrow).
403 Taken together, these results suggest that either the loss or the inversion of island V and its
404 associated CTCF site, had an effect on C-DOM chromatin structure. Nonetheless, this effect
405 did not greatly alter the regulatory landscape chromatin architecture, corroborating the lack of
406 impact on transcription.

407

408 **Group 13 HOX proteins access the TAD structure**

409 Our datasets on single enhancer deletions raise several potential hypotheses (see the
410 discussion). Amongst them the possibility that the transcriptional outcome of the C-DOM
411 regulation may rely upon an unspecific, global effect of accumulating various factors within
412 the landscape architecture, thus licensing the TAD for activation of the target genes. The same
413 C-DOM TAD was previously shown to regulate *Hoxd13* and neighboring *Hoxd* genes during
414 distal limb bud development, a structure that resembles in many respects the developing
415 genitals (Cobb and Duboule, 2005; Cohn, 2011; Infante et al., 2015; Tschopp et al., 2014). In
416 this case, the products of both *Hoxa13* and *Hoxd13* were shown to bind to most of those C-
417 DOM regulatory sequences specific for distal limb buds. From this observation, it was
418 concluded that HOX13 proteins themselves were instrumental in activating or re-enforcing
419 transcription of the *Hoxd13* gene in this developmental context, by accumulating at this
420 landscape and binding to many accessible sites due to their low binding specificity (Beccari et
421 al., 2016; Sheth et al., 2016).

422 In this context, we used an antibody against the HOXA13 product in a CnR approach,
423 with either CR cells at E10.5 or GT cells at E13.5, i.e. before GT formation and during its
424 emergence, respectively. Previous work has shown both redundancy of binding to limb
425 regulatory elements and similarity of DNA binding motifs between HOXA13 and HOXD13
426 (Sheth et al., 2016). As such, and because of the HOXA13 binding profile in our dataset, we
427 consider that this dataset reflects the binding of either HOXA13, HOXD13 or of both proteins
428 and is thus referred to as ‘HOX13’ (Figure 8). We detected enrichment of HOX13 binding
429 signals in both *Hoxd13* regulatory landscapes (Figure 8A; C-DOM and T-DOM) similar to
430 what was observed in distal forelimb at E12.5 (Beccari et al., 2016; Sheth et al., 2016). In CR
431 cells at E10.5, HOX13 binding was found in C-DOM at discrete positions corresponding to
432 previously described regulatory elements, in particular GT1, GT2, and Prox (Figure 8B). All

433 these binding sites and others, with the exception of the Prox enhancer, correlated with
434 accessible chromatin sites as mapped by ATAC-seq (Figure 8B, arrow). In the case of Prox,
435 HOX13 binding was scored before a clear ATAC-seq signal was detected, suggesting a
436 potential role for HOX13 proteins in participating to making some of these sites accessible.
437 The few strong ATAC-seq peaks, which were not matched by HOX13 binding corresponded
438 to non-*Hox* gene promoters (Figure 8B, bottom line).

439 In E13.5 GT cells, as development progressed in parallel with C-DOM becoming fully
440 active, an overall increase of HOX13 binding was scored over C-DOM (Figure 8B). While
441 binding was strengthened at some sites bound at the earlier stage, other elements became both
442 accessible and bound by HOX13 such as the islands II and III regions or a sequence located
443 inside an intron of the *Lnpg* gene (Figure 8B). Overall, a good correlation was observed
444 between the increase of *Hoxd13* transcript levels on the one hand, and both the activation of
445 the C-DOM regulatory landscape and the binding of HOX13, on the other.

446

447 **DISCUSSION**

448 **A preformed chromatin structure with multiple regulatory choices**

449 In mammals, external genitals appear during fetal development as an overgrowth of a
450 mesodermal territory surrounding the cloaca region (Georgas et al., 2015). In the absence of
451 both *Hoxa13* and *Hoxd13* functions, this growth does not occur and the fetus displays a
452 structure resembling that of a cloaca (Kondo et al., 1997; Warot et al., 1997), indicating that
453 the proper transcriptional activation of these two genes in time and space is critical in this
454 context. Studies of the *HoxD* cluster have provided some insights into this question (Lonfat et
455 al., 2014) and suggested that the regulation of *Hoxd13* is primarily achieved by the C-DOM
456 TAD, a large regulatory landscape flanking the gene cluster on its centromeric side, which also
457 controls *Hoxd* gene activation in the developing digits. In the latter case, the chromatin
458 interaction profile displayed some differences in transcriptionally active cells, even though the
459 global TAD structure remained unchanged, suggesting that a C-DOM internal chromatin
460 micro-organization had occurred due to the implementation of various digit-specific enhancers.
461 Because of the close evolutionary neighborhood of digits and external genitals (Cobb and
462 Duboule, 2005; Cohn, 2011; Tschopp et al., 2014), we examined this particular aspect of *Hoxd*
463 gene regulation during the growth of the genital tubercle.

464 We looked at chromatin dynamics at the *Hoxd* locus and observed two types of
465 chromatin interactions. On the one hand, we detected contacts associated with a pre-formed

466 structure, mainly linked to occupied CTCF sites. These contacts were observed independently
467 of the transcriptional status of the cluster, as exemplified by island II and island V. On the other
468 hand, we scored interactions present only when transcriptional activation had occurred such as
469 the Prox and GT2 enhancer sequences. Our time-point series of interaction profiles revealed
470 that the C-DOM TAD seems to be activated in a coordinated manner, with all specific contacts
471 appearing mostly within the same developmental time window, suggesting that the TAD itself
472 may be considered as a global regulatory unit (see below), rather than a field containing a range
473 of disparate enhancers with specific features and acting at different times. Also, the chromatin
474 architecture associated with this specific developmental context was already observed in the
475 E10.5 CR, i.e. before the emergence of the GT. Therefore, this internal-TAD micro-
476 organization predates the outgrowth of the GT structure, which suggests -but does not
477 demonstrate- a causal relationship or at least a necessity for the TAD to be fully primed for the
478 structure to develop.

479

480 **Switching the TAD on and off to prevent regulatory leakages**

481 Our time-series sampling gave us the unique opportunity to follow the C-DOM TAD
482 dynamics in a developing system where most of the cells at E17.5 derive from a homogenous
483 population of mesodermal cells in the nascent genital bud at E12.5, all expressing *Hoxd13*. The
484 highest frequency of interactions with the C-DOM was scored in E12.5 and E13.5 GTs, which
485 correlated with an increase in *Hoxd13* transcription, an enrichment of H3K27ac marks, and
486 increase in binding of HOX13 proteins at discrete enhancer elements. After this time-point, a
487 decrease in *Hoxd* transcript levels were scored in parallel with a reduction of all contacts
488 associated with the active regulatory regions within the C-DOM. By E17.5 the C-DOM
489 structure within the GT was reduced to a framework of constitutive interactions associated to
490 CTCF binding sites, similar to the one observed in ES cells and fetal forebrain cells.

491 This global decrease, observed at a cell population level, can be explained either
492 through a general decrease in transcription or through the selective transcriptional switch-off
493 in some cell types along with their progressive differentiation thus leading to a dilution effect.
494 Detailed ISH analyses (Dolle et al., 1991b; Warot et al., 1997) clearly favors the latter option,
495 whereby some cell types differentiating from the early mesodermal GT precursors turn off C-
496 DOM regulation, whereas others maintain this regulation. At E17.5 indeed, strong *Hoxd13*
497 expression was scored in the anlagen of the *corpus cavernosum* while other cells of the tubercle
498 became negative. Of note, this concentration of positive cells in the blastema and subsequent
499 restriction to the periphery (Dolle et al., 1991b) resembles the situation for *Hoxd13* transcripts

500 during cartilage differentiation in developing digits. In support of this analogy, a penile bone
501 (*baculum*) differentiates from this region in the mouse as in many other mammals.

502 The hereby described changes in the regulatory landscape architecture associated with
503 transcriptional activity seem to be a pervasive feature during development (Andrey et al., 2017;
504 Freire-Pritchett et al., 2017; Phillips-Cremins et al., 2013). We show that when these ‘active’
505 contacts disappear along with transcription being switched off, the TAD structure comes back
506 to an inactive configuration. While such negative ground-state structures may simply reflect
507 the absence of upstream factors and/or represent a scaffold to reinforce future enhancer-
508 promoter contacts (Paliou et al., 2019), it may in our case be functionally required to prevent
509 any transcriptional leakage of *Hoxd13*. HOX13 products are indeed potent dominant negative
510 proteins (Darbellay et al., 2019; Villavicencio-Lorini et al., 2010) and their ectopic production
511 in time and space must be prevented for proper development to be achieved (Young et al.,
512 2009). A rapid return to an inactive chromatin conformation of C-DOM may help control this
513 aspect, unlike other contexts where a particular chromatin topology is maintained for a long
514 time (Fernandez-Albert et al., 2019).

515

516 **Mechanism(s) of action of long-range enhancers**

517 The complex pleiotropic expressions of vertebrate *Hox* genes, as well as of many other
518 developmental genes, are usually controlled by multiple enhancers, either regulating subsets of
519 the global pattern, or acting together in a partially redundant manner (Long et al., 2016;
520 Montavon et al., 2011; Spitz and Furlong, 2012). We tested the potential function either of
521 large DNA segments, or of shorter candidate regulatory regions within these segments and
522 obtained different results depending on the position of the segment considered within C-DOM.
523 When the *rel5* to *SB* DNA fragment was deleted, a substantial decrease in *Hoxd13* transcription
524 was observed. However, the deletion of any single candidate sequence in isolation identified
525 within this segment did not elicit any detectable decrease in transcription. This systematic
526 analysis echoes previous studies where deleting a single and well-characterized enhancer did
527 not have the expected effect upon its target gene (e.g. (Cretokos et al., 2008; Frankel et al.,
528 2010; Osterwalder et al., 2018).

529 In contrast, the deletion of Prox resulted in a decrease in *Hoxd13* transcripts, which in
530 itself could account for the decrease observed when the *rel1* to *rel5* DNA fragment was deleted.
531 This occurred in the absence of any major reorganization either of the chromatin architecture,
532 or of its accessibility to factors. Therefore, Prox seemed to act independently of the other
533 elements in C-DOM, as initially expected for a ‘classical’ enhancer sequence. Concerning the

534 elements located within the *rel5* to *SB* central part of C-DOM whose deletions in isolation had
535 no detectable effect, they could be functionally redundant with one another or, alternatively,
536 compensatory mechanisms could be implemented for instance to re-direct the lost interactions
537 towards another enhancer. Also, evolution might have selected regulatory processes to cope
538 when facing particular conditions not necessarily tractable in laboratory conditions (Frankel et
539 al., 2010; Hong et al., 2008). Our transgenic assays revealed that at least partial overlap in the
540 functional domains was sometimes observed (GT2, GT1, Prox), whereas in other cases,
541 transgenic sequences elicited complementary domain of expression (IIIE and IVE). Therefore,
542 some functional overlap between enhancers may account for the absence of phenotype
543 (Osterwalder et al., 2018). Finally, it is possible either that our experimental approach lacks
544 the resolution required to discern mild alterations in gene expression, perhaps occurring in a
545 subpopulation of cells, or that individual C-DOM enhancers elements may control gene
546 expression at distinct developmental stages. In the latter scenario, we may have missed the
547 enhancer function by focusing our analyses in only selected developmental time-point. Support
548 for this alternative was provided by our results showing a decrease of *Hoxd13* mRNA in
549 *del(GT2)* CR at E10.5.

550 Besides these potential explanations, the binding of HOX13 proteins to most -if not all-
551 these C-DOM regulatory sequences raise yet another potential explanation related to recent
552 work showing that phase-separation-induced condensates of RNA Pol II, transcription factors
553 (TF) and the Mediator complex are present at particular enhancers leading to transcriptional
554 activation (Boija et al., 2018; Hnisz et al., 2017; Sabari et al., 2018). In this view, condensate
555 formation would be beneficial for transcriptional activation and could be promoted by the
556 aggregation of protein containing intrinsically disordered regions (Kato et al., 2012). Both
557 HOXD13 and HOXA13 contain long stretches of monotonic amino-acids (poly-Ala, Poly-Glu,
558 Poly-Ser) (Akarsu, 1996; Mortlock and Innis, 1997; Muragaki et al., 1996), which could thus
559 contribute to the building of this micro-environment by using the TAD as a scaffold. Naturally-
560 occurring modifications in the lengths of these amino-acids repeats were shown to drastically
561 affect the function of HOX13 proteins (Bruneau et al., 2001; Muragaki et al., 1996; Utsch et
562 al., 2002). Yet their effects upon a potential regulatory structure has not yet been evaluated.
563 Binding of HOX13 proteins over C-DOM involved most -yet not all- sequences determined
564 accessible by ATAC-seq. In the case of the Prox sequence a robust association was detected
565 by CnR before an ATAC-seq peak could be scored, in support of the idea that HOX13 protein
566 may in some instances display a pioneer effect (Desanlis et al., 2019).

567

568 **CTCF and the loop extrusion model *in embryo***

569 The *Rel5-SB* sub-region of C-DOM contains the largest series of defined GT regulatory
570 sequences involved in *Hoxd13* regulation. Within this region lies island V, which contains the
571 only occupied CTCF site in the central part of C-DOM. We thus assumed that this site would
572 be instrumental to bring these enhancers towards the *HoxD* cluster through looping. Also, this
573 element is one of the two constitutive contacts maintained in the absence of transcription (along
574 with island II). After inversion of island V and the CTCF site contained within, the effects upon
575 the global chromatin architecture were marginal. This result is in line with the lack of
576 transcriptional decrease observed upon deleting this element. All other identified regulatory
577 sequences located nearby were still able to contact *Hoxd13* with the same profile, suggesting
578 that this CTCF site had no major role in securing interactions between these enhancers and
579 *Hoxd13*, similar to what was suggested at another developmentally regulated locus
580 (Williamson et al., 2019).

581 The inversion of island V and its CTCF site nevertheless resulted in a global decrease
582 of interactions with *Hoxd13*, balanced by an increase in interactions with the centromeric
583 region containing distal CTCF sites. After inversion, these CTCF sites were now facing the
584 island V CTCF binding site and hence these partial redistributions of interactions are in
585 agreement with the loop extrusion model (de Wit et al., 2015; Rao et al., 2014; Vietri Rudan et
586 al., 2015). While the inversion of island V thus resulted in a slight reallocation of intra-TAD
587 interactions, they were not sufficient to elicit changes in gene expression and had negligible
588 impact on long-range regulation of *Hoxd* genes by C-DOM. Alternatively, we may be missing
589 the time resolution to observe the impact of removing these sites.

590

591 **REFERENCES**

592

- 593 Afgan E, Baker D, van den Beek M, Blankenberg D, Bouvier D, Čech M, Chilton J,
594 Clements D, Coraor N, Eberhard C, Grüning B, Guerler A, Hillman-Jackson J, Von Kuster
595 G, Rasche E, Soranzo N, Turaga N, Taylor J, Nekrutenko A, Goecks J. 2016. The Galaxy
596 platform for accessible, reproducible and collaborative biomedical analyses: 2016 update.
597 *Nucleic Acids Res* **44**:W3–W10. doi:10.1093/nar/gkw343
- 598 Akarsu A. 1996. Genomic structure of HOXD13 gene: a nine polyalanine duplication causes
599 synpolydactyly in two unrelated families. *Human Molecular Genetics* **5**:945–952.
600 doi:10.1093/hmg/5.7.945
- 601 Amândio AR, Necsulea A, Joye E, Mascrez B, Duboule D. 2016. Hotair Is Dispensable for
602 Mouse Development. *PLoS Genet* **12**:e1006232. doi:10.1371/journal.pgen.1006232
- 603 Andrey G, Montavon T, Mascrez B, Gonzalez F, Noordermeer D, Leleu M, Trono D, Spitz F,
604 Duboule D. 2013. A switch between topological domains underlies HoxD genes collinearity
605 in mouse limbs. *Science* **340**:1234167. doi:10.1126/science.1234167

- 606 Andrey G, Schöpflin R, Jerković I, Heinrich V, Ibrahim DM, Paliou C, Hochradel M,
607 Timmermann B, Haas S, Vingron M, Mundlos S. 2017. Characterization of hundreds of
608 regulatory landscapes in developing limbs reveals two regimes of chromatin folding. *Genome*
609 *Res* **27**:223–233. doi:10.1101/gr.213066.116
- 610 Beccari L, Yakushiji-Kaminatsui N, Woltering JM, Necsulea A, Lonfat N, Rodriguez-
611 Carballo E, Mascrez B, Yamamoto S, Kuroiwa A, Duboule D. 2016. A role for HOX13
612 proteins in the regulatory switch between TADs at the HoxD locus. *Genes Dev* **30**:1172–86.
613 doi:10.1101/gad.281055.116
- 614 Boija A, Klein IA, Sabari BR, Dall’Agnese A, Coffey EL, Zamudio AV, Li CH, Shrinivas K,
615 Manteiga JC, Hannett NM, Abraham BJ, Afeyan LK, Guo YE, Rimel JK, Fant CB, Schuijers
616 J, Lee TI, Taatjes DJ, Young RA. 2018. Transcription Factors Activate Genes through the
617 Phase-Separation Capacity of Their Activation Domains. *Cell* **175**:1842-1855.e16.
618 doi:10.1016/j.cell.2018.10.042
- 619 Bruneau S, Johnson KR, Yamamoto M, Kuroiwa A, Duboule D. 2001. The mouse
620 Hoxd13(spdh) mutation, a polyalanine expansion similar to human type II synpolydactyly
621 (SPD), disrupts the function but not the expression of other Hoxd genes. *Dev Biol* **237**:345–
622 53. doi:10.1006/dbio.2001.0382
- 623 Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. 2013. Transposition of native
624 chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding
625 proteins and nucleosome position. *Nat Methods* **10**:1213–1218. doi:10.1038/nmeth.2688
- 626 Cobb J, Duboule D. 2005. Comparative analysis of genes downstream of the Hoxd cluster in
627 developing digits and external genitalia. *Development* **132**:3055–67. doi:10.1242/dev.01885
- 628 Cohn MJ. 2011. Development of the external genitalia: Conserved and divergent mechanisms
629 of appendage patterning. *Dev Dyn* **240**:1108–1115. doi:10.1002/dvdy.22631
- 630 Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini
631 LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. *Science*
632 **339**:819–23. doi:10.1126/science.1231143
- 633 Cretekos CJ, Wang Y, Green ED, Martin JF, Rasweiler JJ th, Behringer RR. 2008.
634 Regulatory divergence modifies limb length between mammals. *Genes Dev* **22**:141–51.
635 doi:10.1101/gad.1620408
- 636 Darbellay F, Bochaton C, Lopez-Delisle L, Mascrez B, Tschopp P, Delpretti S, Zakany J,
637 Duboule D. 2019. The constrained architecture of mammalian Hox gene clusters. *Proc Natl*
638 *Acad Sci USA* **116**:13424–13433. doi:10.1073/pnas.1904602116
- 639 David FP, Delafontaine J, Carat S, Ross FJ, Lefebvre G, Jarosz Y, Sinclair L, Noordermeer
640 D, Rougemont J, Leleu M. 2014. HTSstation: a web application and open-access libraries for
641 high-throughput sequencing data analysis. *PloS one* **9**:e85879.
642 doi:10.1371/journal.pone.0085879
- 643 de Wit E, Vos ES, Holwerda SJ, Valdes-Quezada C, Verstegen MJ, Teunissen H, Splinter E,
644 Wijchers PJ, Krijger PH, de Laat W. 2015. CTCF Binding Polarity Determines Chromatin
645 Looping. *Molecular cell* **60**:676–84. doi:10.1016/j.molcel.2015.09.023
- 646 Desanlis I, Kherdjemil Y, Mayran A, Bouklouch Y, Gentile C, Sheth R, Zeller R, Drouin J,
647 Kmita M. 2019. HOX13-dependent chromatin accessibility modulates the target repertoires
648 of the HOX factors (preprint). *Developmental Biology*. doi:10.1101/789875
- 649 Dolle P, Dierich A, LeMeur M, Schimmang T, Schuhbaur B, Chambon P, Duboule D. 1993.
650 Disruption of the Hoxd-13 gene induces localized heterochrony leading to mice with neonenic
651 limbs. *Cell* **75**:431–41.
- 652 Dolle P, Izpisua-Belmonte JC, Boncinelli E, Duboule D. 1991a. The Hox-4.8 gene is
653 localized at the 5’ extremity of the Hox-4 complex and is expressed in the most posterior
654 parts of the body during development. *Mech Dev* **36**:3–13.
- 655 Dolle P, Izpisua-Belmonte JC, Brown JM, Tickle C, Duboule D. 1991b. HOX-4 genes and

- 656 the morphogenesis of mammalian genitalia. *Genes Dev* **5**:1767–7.
- 657 Fernandez-Albert J, Lipinski M, Lopez-Cascales MT, Rowley MJ, Martin-Gonzalez AM, Del
658 Blanco B, Corces VG, Barco A. 2019. Immediate and deferred epigenomic signatures of in
659 vivo neuronal activation in mouse hippocampus. *Nat Neurosci* **22**:1718–1730.
660 doi:10.1038/s41593-019-0476-2
- 661 Frankel N, Davis GK, Vargas D, Wang S, Payre F, Stern DL. 2010. Phenotypic robustness
662 conferred by apparently redundant transcriptional enhancers. *Nature* **466**:490–3.
663 doi:10.1038/nature09158
- 664 Freire-Pritchett P, Schoenfelder S, Várnai C, Wingett SW, Cairns J, Collier AJ, García-
665 Vilchez R, Furlan-Magaril M, Osborne CS, Fraser P, Rugg-Gunn PJ, Spivakov M. 2017.
666 Global reorganisation of cis-regulatory units upon lineage commitment of human embryonic
667 stem cells. *eLife* **6**:e21926. doi:10.7554/eLife.21926
- 668 Fudenberg G, Imakaev M, Lu C, Goloborodko A, Abdennur N, Mirny LA. 2016. Formation
669 of Chromosomal Domains by Loop Extrusion. *Cell Rep* **15**:2038–49.
670 doi:10.1016/j.celrep.2016.04.085
- 671 Georgas KM, Armstrong J, Keast JR, Larkins CE, McHugh KM, Southard-Smith EM, Cohn
672 MJ, Batourina E, Dan H, Schneider K, Buehler DP, Wiese CB, Brennan J, Davies JA,
673 Harding SD, Baldock RA, Little MH, Vezina CM, Mendelsohn C. 2015. An illustrated
674 anatomical ontology of the developing mouse lower urogenital tract. *Development* **142**:1893–
675 1908. doi:10.1242/dev.117903
- 676 Gonzalez F, Duboule D, Spitz F. 2007. Transgenic analysis of Hoxd gene regulation during
677 digit development. *Dev Biol* **306**:847–59.
- 678 Hashimoto M, Takemoto T. 2015. Electroporation enables the efficient mRNA delivery into
679 the mouse zygotes and facilitates CRISPR/Cas9-based genome editing. *Scientific Reports* **5**.
680 doi:10.1038/srep11315
- 681 Herault Y, Hraba-Renevey S, van der Hoeven F, Duboule D. 1996. Function of the Evx-2
682 gene in the morphogenesis of vertebrate limbs. *EMBO J* **15**:6727–38.
- 683 Hnisz D, Shrinivas K, Young RA, Chakraborty AK, Sharp PA. 2017. A Phase Separation
684 Model for Transcriptional Control. *Cell* **169**:13–23. doi:10.1016/j.cell.2017.02.007
- 685 Hong J-W, Hendrix DA, Levine MS. 2008. Shadow enhancers as a source of evolutionary
686 novelty. *Science* **321**:1314. doi:10.1126/science.1160631
- 687 Hostikka SL, Capecchi MR. 1998. The mouse Hoxc11 gene: genomic structure and
688 expression pattern. *Mechanisms of development* **70**:133–45.
- 689 Infante CR, Mihala AG, Park S, Wang JS, Johnson KK, Lauderdale JD, Menke DB. 2015.
690 Shared Enhancer Activity in the Limbs and Phallus and Functional Divergence of a Limb-
691 Genital cis-Regulatory Element in Snakes. *Developmental Cell* **35**:107–119.
692 doi:10.1016/j.devcel.2015.09.003
- 693 Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J,
694 Grishin NV, Frantz DE, Schneider JW, Chen S, Li L, Sawaya MR, Eisenberg D, Tycko R,
695 McKnight SL. 2012. Cell-free Formation of RNA Granules: Low Complexity Sequence
696 Domains Form Dynamic Fibers within Hydrogels. *Cell* **149**:753–767.
697 doi:10.1016/j.cell.2012.04.017
- 698 Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. 2013. TopHat2: accurate
699 alignment of transcriptomes in the presence of insertions, deletions and gene fusions.
700 *Genome biology* **14**:R36. doi:10.1186/gb-2013-14-4-r36
- 701 Kondo T, Zákány J, Innis JW, Duboule D. 1997. Of fingers, toes and penises. *Nature*
702 **390**:29–29. doi:10.1038/36234
- 703 Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
704 **9**:357–9. doi:10.1038/nmeth.1923
- 705 Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA,

- 706 Copeland NG. 2001. A highly efficient Escherichia coli-based chromosome engineering
707 system adapted for recombinogenic targeting and subcloning of BAC DNA. *Genomics*
708 **73**:56–65. doi:10.1006/geno.2000.6451
- 709 Lonfat N. 2013. An ancestral regulatory mechanism underlies Hoxd gene expression in both
710 developing genitals and digits. doi:10.5075/epfl-thesis-5997
- 711 Lonfat N, Duboule D. 2015. Structure, function and evolution of topologically associating
712 domains (TADs) at HOX loci. *FEBS letters* **589**:2869–76. doi:10.1016/j.febslet.2015.04.024
- 713 Lonfat N, Montavon T, Darbellay F, Gitto S, Duboule D. 2014. Convergent evolution of
714 complex regulatory landscapes and pleiotropy at Hox loci. *Science* **346**:1004–6.
715 doi:10.1126/science.1257493
- 716 Long HK, Prescott SL, Wysocka J. 2016. Ever-Changing Landscapes: Transcriptional
717 Enhancers in Development and Evolution. *Cell* **167**:1170–1187.
718 doi:10.1016/j.cell.2016.09.018
- 719 Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing
720 reads. *EMBnet journal* **17**. doi:10.14806/ej.17.1.200
- 721 Mashiko D, Fujihara Y, Satouh Y, Miyata H, Isotani A, Ikawa M. 2013. Generation of
722 mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided
723 RNA. *Sci Rep* **3**:3355. doi:10.1038/srep03355
- 724 Meers MP, Tenenbaum D, Henikoff S. 2019. Peak calling by Sparse Enrichment Analysis for
725 CUT&RUN chromatin profiling. *Epigenetics Chromatin* **12**:42. doi:10.1186/s13072-019-
726 0287-4
- 727 Montavon T, Le Garrec J-F, Kerszberg M, Duboule D. 2008. Modeling Hox gene regulation
728 in digits: reverse collinearity and the molecular origin of thumbness. *Genes Dev* **22**:346–59.
729 doi:10.1101/gad.1631708
- 730 Montavon T, Soshnikova N, Mascrez B, Joye E, Thevenet L, Splinter E, de Laat W, Spitz F,
731 Duboule D. 2011. A regulatory archipelago controls Hox genes transcription in digits. *Cell*
732 **147**:1132–45. doi:10.1016/j.cell.2011.10.023
- 733 Mortlock DP, Innis JW. 1997. Mutation of HOXA13 in hand-foot-genital syndrome. *Nat*
734 *Genet* **15**:179–80. doi:10.1038/ng0297-179
- 735 Muragaki Y, Mundlos S, Upton J, Olsen BR. 1996. Altered Growth and Branching Patterns
736 in Synpolydactyly Caused by Mutations in HOXD13. *Science* **272**:548–551.
737 doi:10.1126/science.272.5261.548
- 738 Noordermeer D, Leleu M, Schorderet P, Joye E, Chabaud F, Duboule D. 2014. Temporal
739 dynamics and developmental memory of 3D chromatin architecture at Hox gene loci. *eLife*
740 **3**:e02557. doi:10.7554/eLife.02557
- 741 Noordermeer D, Leleu M, Splinter E, Rougemont J, De Laat W, Duboule D. 2011. The
742 dynamic architecture of Hox gene clusters. *Science* **334**:222–5. doi:10.1126/science.1207194
- 743 Ong CT, Corces VG. 2014. CTCF: an architectural protein bridging genome topology and
744 function. *Nat Rev Genet* **15**:234–46. doi:10.1038/nrg3663
- 745 Osterwalder M, Barozzi I, Tissières V, Fukuda-Yuzawa Y, Mannion BJ, Afzal SY, Lee EA,
746 Zhu Y, Plajzer-Frick I, Pickle CS, Kato M, Garvin TH, Pham QT, Harrington AN, Akiyama
747 JA, Afzal V, Lopez-Rios J, Dickel DE, Visel A, Pennacchio LA. 2018. Enhancer redundancy
748 provides phenotypic robustness in mammalian development. *Nature* **554**:239–243.
749 doi:10.1038/nature25461
- 750 Paliou C, Guckelberger P, Schöpflin R, Heinrich V, Esposito A, Chiariello AM, Bianco S,
751 Annunziatella C, Helmuth J, Haas S, Jerković I, Brieske N, Wittler L, Timmermann B,
752 Nicodemi M, Vingron M, Mundlos S, Andrey G. 2019. Preformed chromatin topology assists
753 transcriptional robustness of *Shh* during limb development. *Proc Natl Acad Sci USA*
754 **116**:12390–12399. doi:10.1073/pnas.1900672116
- 755 Phillips-Cremins JE, Sauria ME, Sanyal A, Gerasimova TI, Lajoie BR, Bell JS, Ong CT,

756 Hookway TA, Guo C, Sun Y, Bland MJ, Wagstaff W, Dalton S, McDevitt TC, Sen R,
757 Dekker J, Taylor J, Corces VG. 2013. Architectural Protein Subclasses Shape 3D
758 Organization of Genomes during Lineage Commitment. *Cell* **153**:1281–95.
759 Quinlan AR. 2014. BEDTools: The Swiss-Army Tool for Genome Feature Analysis. *Current*
760 *protocols in bioinformatics / editorial board, Andreas D Baxevanis . [et al]* **47**:11 12 1-11 12
761 34. doi:10.1002/0471250953.bi1112s47
762 Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, Sanborn AL,
763 Machol I, Omer AD, Lander ES, Aiden EL. 2014. A 3D map of the human genome at
764 kilobase resolution reveals principles of chromatin looping. *Cell* **159**:1665–80.
765 doi:10.1016/j.cell.2014.11.021
766 Roberts A, Trapnell C, Donaghey J, Rinn JL, Pachter L. 2011. Improving RNA-Seq
767 expression estimates by correcting for fragment bias. *Genome biology* **12**:R22.
768 doi:10.1186/gb-2011-12-3-r22
769 Rodriguez-Carballo E, Lopez-Delisle L, Zhan Y, Fabre PJ, Beccari L, El-Idrissi I, Huynh
770 THN, Ozadam H, Dekker J, Duboule D. 2017. The HoxD cluster is a dynamic and resilient
771 TAD boundary controlling the segregation of antagonistic regulatory landscapes. *Genes Dev*
772 **31**:2264–2281. doi:10.1101/gad.307769.117
773 Sabari BR, Dall’Agnese A, Boija A, Klein IA, Coffey EL, Shrinivas K, Abraham BJ, Hannett
774 NM, Zamudio AV, Manteiga JC, Li CH, Guo YE, Day DS, Schuijers J, Vasile E, Malik S,
775 Hnisz D, Lee TI, Cisse II, Roeder RG, Sharp PA, Chakraborty AK, Young RA. 2018.
776 Coactivator condensation at super-enhancers links phase separation and gene control. *Science*
777 **361**. doi:10.1126/science.aar3958
778 Schmid M, Durussel T, Laemmlli UK. 2004. ChIC and ChEC; genomic mapping of chromatin
779 proteins. *Mol Cell* **16**:147–157. doi:10.1016/j.molcel.2004.09.007
780 Sheth R, Barozzi I, Langlais D, Osterwalder M, Nemeč S, Carlson HL, Stadler HS, Visel A,
781 Drouin J, Kmita M. 2016. Distal Limb Patterning Requires Modulation of cis-Regulatory
782 Activities by HOX13. *Cell Rep* **17**:2913–2926. doi:10.1016/j.celrep.2016.11.039
783 Skene PJ, Henikoff JG, Henikoff S. 2018. Targeted in situ genome-wide profiling with high
784 efficiency for low cell numbers. *Nat Protoc* **13**:1006–1019. doi:10.1038/nprot.2018.015
785 Skene PJ, Henikoff S. 2017. An efficient targeted nuclease strategy for high-resolution
786 mapping of DNA binding sites. *Elife* **6**. doi:10.7554/eLife.21856
787 Soshnikova N, Montavon T, Leleu M, Galjart N, Duboule D. 2010. Functional analysis of
788 CTCF during mammalian limb development. *Dev Cell* **19**:819–30.
789 doi:10.1016/j.devcel.2010.11.009
790 Spitz F, Furlong EE. 2012. Transcription factors: from enhancer binding to developmental
791 control. *Nature reviews Genetics* **13**:613–26. doi:10.1038/nrg3207
792 Spitz F, Gonzalez F, Duboule D. 2003. A global control region defines a chromosomal
793 regulatory landscape containing the HoxD cluster. *Cell* **113**:405–17.
794 Stemmer M, Thumberger T, Del Sol Keyer M, Wittbrodt J, Mateo JL. 2015. CCTop: An
795 Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. *PLoS ONE*
796 **10**:e0124633. doi:10.1371/journal.pone.0124633
797 Tschopp P, Duboule D. 2011. A regulatory “landscape effect” over the HoxD cluster.
798 *Developmental biology* **351**:288–96. doi:10.1016/j.ydbio.2010.12.034
799 Tschopp P, Sherratt E, Sanger TJ, Groner AC, Aspiras AC, Hu JK, Pourquie O, Gros J, Tabin
800 CJ. 2014. A relative shift in cloacal location repositions external genitalia in amniote
801 evolution. *Nature* **516**:391–4. doi:10.1038/nature13819
802 Utsch B, Becker K, Brock D, Lentze MJ, Bidlingmaier F, Ludwig M. 2002. A novel stable
803 polyalanine [poly(A)] expansion in the HOXA13 gene associated with hand-foot-genital
804 syndrome: proper function of poly(A)-harbouring transcription factors depends on a critical
805 repeat length? *Hum Genet* **110**:488–494. doi:10.1007/s00439-002-0712-8

806 Vian L, Pękowska A, Rao SSP, Kieffer-Kwon K-R, Jung S, Baranello L, Huang S-C, El
807 Khattabi L, Dose M, Pruett N, Sanborn AL, Canela A, Maman Y, Oksanen A, Resch W, Li
808 X, Lee B, Kovalchuk AL, Tang Z, Nelson S, Di Pierro M, Cheng RR, Machol I, St Hilaire
809 BG, Durand NC, Shamim MS, Stamenova EK, Onuchic JN, Ruan Y, Nussenzweig A,
810 Levens D, Aiden EL, Casellas R. 2018. The Energetics and Physiological Impact of Cohesin
811 Extrusion. *Cell* **175**:292–294. doi:10.1016/j.cell.2018.09.002
812 Vietri Rudan M, Barrington C, Henderson S, Ernst C, Odom DT, Tanay A, Hadjur S. 2015.
813 Comparative Hi-C reveals that CTCF underlies evolution of chromosomal domain
814 architecture. *Cell reports* **10**:1297–309. doi:10.1016/j.celrep.2015.02.004
815 Vieux-Rochas M, Fabre PJ, Leleu M, Duboule D, Noordermeer D. 2015. Clustering of
816 mammalian Hox genes with other H3K27me3 targets within an active nuclear domain.
817 *Proceedings of the National Academy of Sciences of the United States of America* **112**:4672–
818 7. doi:10.1073/pnas.1504783112
819 Villavicencio-Lorini P, Kuss P, Friedrich J, Haupt J, Farooq M, Turkmen S, Duboule D,
820 Hecht J, Mundlos S. 2010. Homeobox genes d11-d13 and a13 control mouse autopod cortical
821 bone and joint formation. *The Journal of clinical investigation* **120**:1994–2004.
822 doi:10.1172/JCI41554
823 Warot X, Fromental-Ramain C, Fraulob V, Chambon P, Dolle P. 1997. Gene dosage-
824 dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal
825 parts of the digestive and urogenital tracts. *Development* **124**:4781–91.
826 Williamson I, Kane L, Devenney PS, Flyamer IM, Anderson E, Kilanowski F, Hill RE,
827 Bickmore WA, Lettice LA. 2019. Developmentally regulated Shh expression is robust to
828 TAD perturbations. *Development* **146**. doi:10.1242/dev.179523
829 Woltering JM, Noordermeer D, Leleu M, Duboule D. 2014. Conservation and divergence of
830 regulatory strategies at Hox Loci and the origin of tetrapod digits. *PLoS Biol* **12**:e1001773.
831 doi:10.1371/journal.pbio.1001773
832 Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, Cummins C,
833 Clapham P, Fitzgerald S, Gil L, Giron CG, Gordon L, Hourlier T, Hunt SE, Janacek SH,
834 Johnson N, Juettemann T, Keenan S, Lavidas I, Martin FJ, Maurel T, McLaren W, Murphy
835 DN, Nag R, Nuhn M, Parker A, Patricio M, Pignatelli M, Rahtz M, Riat HS, Sheppard D,
836 Taylor K, Thormann A, Vullo A, Wilder SP, Zadissa A, Birney E, Harrow J, Muffato M,
837 Perry E, Ruffier M, Spudich G, Trevanion SJ, Cunningham F, Aken BL, Zerbino DR, Flicek
838 P. 2016. Ensembl 2016. *Nucleic acids research* **44**:D710-6. doi:10.1093/nar/gkv1157
839 Young T, Rowland JE, van de Ven C, Bialecka M, Novoa A, Carapuco M, van Nes J, de
840 Graaff W, Duluc I, Freund JN, Beck F, Mallo M, Deschamps J. 2009. Cdx and Hox genes
841 differentially regulate posterior axial growth in mammalian embryos. *Developmental cell*
842 **17**:516–26. doi:10.1016/j.devcel.2009.08.010
843 Zhang Y, Liu T, Meyer CA, Eeckhoutte J, Johnson DS, Bernstein BE, Nusbaum C, Myers
844 RM, Brown M, Li W, Liu XS. 2008. Model-based analysis of CHIP-Seq (MACS). *Genome*
845 *Biol* **9**:R137. doi:10.1186/gb-2008-9-9-r137
846 Ziebarth JD, Bhattacharya A, Cui Y. 2012. CTCFBSDB 2.0: a database for CTCF-binding
847 sites and genome organization. *Nucleic Acids Research* **41**:D188–D194.
848 doi:10.1093/nar/gks1165
849

850 **LEGENDS TO FIGURES**

851

852 **Figure 1: Transcription of *Hoxd* genes in developing GT.** **A)** Quantification of *Hoxd* genes
853 transcript levels by RNA-seq (FPKM values) in GT at E12.5 (Amândio et al., 2016), E16.5 and
854 E18.5. **B)** RT-qPCR of *Hoxd13* mRNAs in different stages of GT development. The plotted
855 values indicate the ratio of expression using the cloaca region (CR) as a reference ($n \geq 3$
856 biological replicates for each sample). A Welch's *t*-test was used to evaluate the putative
857 significant changes in *Hoxd13* expression. Bars indicate mean with SD, **** $p < 0.0001$,
858 * $p = 0.0175$. **C-E)** ATAC-seq (gray) and ChIP-seq profiles for H3K27ac (blue) and H3K27me3
859 (red) at the *HoxD* locus in E10.5 wildtype CR (**C**), E13.5 GT (**D**) and E17.5 GT (**E**).
860 Coordinates (mm10): chr2:74637433-74775728. The gray box in track 3 indicates the
861 enrichment of H3K27me3 at 5'-located *Hoxd* genes in the CR. The gray box in track 8 indicates
862 the relative gain of H3K27me3 at 5'-located *Hoxd* genes in E17.5 GT when compared to the
863 E13.5 GT sample.

864

865 **Figure 2: Chromatin topology of C-DOM during GT development.** **A)** Schematic
866 representation of the two regulatory landscapes, with the centromeric (C-DOM) and telomeric
867 (T-DOM) TADs flanking the *HoxD* cluster (black box), which acts as a boundary. Gray boxes
868 represent non-*Hox* genes. The *cis*-regulatory elements involved in the control of *Hoxd* gene
869 transcription in the GT are located in C-DOM (blue arrow). **B)** 4C-seq interactions profiles
870 between the *Hoxd13* viewpoint (gray line) and both the *HoxD* cluster and the C-DOM. From
871 top to bottom, 4C-seq profiles from mouse ES cells (mESC; track 1) (Noordermeer et al., 2014),
872 E10.5 CR, E12.5 GT, E13.5 GT, E15.5 GT, E17.5 GT and fetal forebrain cells (track 7) are
873 represented. Coordinates (mm10): chr2:73815520-74792376. A schematic representation of
874 the *HoxD* cluster and the C-DOM is shown below, known enhancers are represented by black
875 boxes. The percentages in gray represent the ratio, using mouse ES cells as a reference, of the
876 sum of the fragments in the centromeric gene desert, divided by the sum of fragments that fall
877 in a non-interacting region of the T-DOM (chr2:75166258-75571741). Blue lines highlight the
878 changes in chromatin interactions between *Hoxd13* and Prox or GT2 in the different
879 developmental stages and tissues analyzed. Red lines highlight that the contacts between
880 *Hoxd13* and island II or island V remained fairly constant in all samples analyzed.

881

882 **Figure 3: Various segments of C-DOM contribute to *Hoxd13* transcription in the GT. A)**

883 The gray tracks show ATAC-seq profiles of E10.5 CR (average of two biological replicates,
884 track 1) and E13.5 GT (average of three biological replicates, track 2). The blue tracks are
885 ChIP-seq for H3K27ac with E13.5 GT (track 3) and E17.5 GT (track 4). Coordinates (mm10):
886 chr2: 73815520-74792376. A schematic representation of the *HoxD* cluster and the C-DOM is
887 shown below, known enhancers are represented by black boxes. The red arrowheads represent
888 the deletions breakpoints. The four large deletion alleles analyzed are depicted as gray dashed
889 lines with scissors. **B-E)** RT-qPCR of *Hoxd* genes mRNAs for wildtype and homozygous
890 mutant deletion alleles using E12.5 GT. The mutant allele is indicated on top of each plot. The
891 values plotted indicate the ratio of mRNA levels using wildtype as a reference (black dots)
892 (n=4 biologically independent wildtype or mutant GT). A Welch's *t*-test was used to evaluate
893 the statistical significance of changes in gene expression. Bars indicate mean with SD, * p≤0.02;
894 ** p≤0.007; *** p≤0.0005, ****p≤0.0001; ns= non-significant.

895

896 **Figure 4: Deletion of the Prox enhancer. A)** Schematic representation of the *HoxD* cluster

897 and the C-DOM with the deletion of the Prox sequence leading to the *Del(Prox)* allele. **B)** X-
898 gal staining showing the activity of the Prox enhancer. **C)** *Hoxd13* transcripts levels obtained
899 by RT-qPCR using wildtype and homozygous mutant *Del(Prox)* GTs at E12.5. The values
900 plotted indicate the ratio of expression using wildtype as a reference (black dots) (n=4
901 biologically independent WT or mutant GTs). A Welch's *t*-test was used to evaluate the
902 statistical significance expression changes. Bars indicate mean with SD, ** p=0.006). **D)** WISH
903 using the *Hoxd13* probe in both wildtype and mutant *Del(Prox)* E12.5 embryos. The *Hoxd13*
904 expression pattern remained unchanged. **E)** ATAC-seq profiles covering C-DOM and *HoxD*
905 in wildtype (top) and *Del(Prox)* mutant (bottom) E13.5 GTs. Coordinates (mm10):
906 chr2:73815520-74792376. The wildtype profile is the average of three biological replicates
907 whereas the *Del(Prox)* represents the average of two biological replicates. Peaks called using
908 MACS2 are displayed under the corresponding tracks (vertical black lines) for each individual
909 replicate. Black arrows highlight the deleted region. **F)** 4C-seq profiles (average of two
910 biological replicates) of wildtype and mutant *Del(Prox)* E13.5 GTs. The *Hoxd13* viewpoint is
911 shown as a gray line. The overlay of the two tracks wildtype (blue) and *Del(Prox)* (red) (bottom
912 track) highlight the loss of the Prox enhancer in the *Del(Prox)* allele and the lack of major
913 alterations in the frequency of contacts between *Hoxd13* and discrete *cis*-regulatory elements.
914 Coordinates (mm10): chr2:73815520-74792376.

915

916 **Figure 5: Activity of C-DOM regulatory elements *in vivo*.** **A)** Schematic representation of
917 C-DOM and the *HoxD* cluster. Previously characterized enhancers are shown as black boxes
918 and red arrowheads point to the SB and rel5 breakpoints. **B)** ATAC-seq profile (top, average
919 of three biological replicates) and H3K27ac ChIP-seq profile (bottom) of E13.5 GTs, focusing
920 on the DNA interval between rel5 and SB (coordinates mm10: chr2:74084880-74432824). The
921 vertical blue lines below the H3K27ac ChIP-seq profile represent the output of the MACS2
922 peak caller tool using the corresponding input as control. **C)** Enhancer transgene activity of all
923 the individual regulatory sub-regions analyzed within the rel5 to SB interval. The gray dashed
924 line boxes represent the tested sub-regions as well as the GT2 sequence. For each clone, a
925 representative staining is shown at E13.5.

926

927 **Figure 6: Serial deletions of single *cis*-regulatory elements.** **A)** Schematic representation of
928 the alleles generated by CRISPR-Cas9 editing *in vivo*. **B)** Relative expression of *Hoxd13*
929 obtained by RT-qPCR of both wildtype control and the various mutant alleles using E12.5 GT
930 cells. The values plotted indicate the ratio of expression using wildtype as a reference (black
931 dots) for each gene ($n \geq 3$ biologically independent wildtype and mutant GTs). **C)** WISH using
932 the *Hoxd13* probe and both wildtype and mutant E12.5 littermates. Both the mRNA levels and
933 transcripts distribution remained globally unchanged.

934

935 **Figure 7: Deletion and inversion of the island V CTCF site *in vivo*.** **A)** CTCF ChIP-seq
936 profiles of wildtype and *Del(V)* mutant E13.5 GTs. Cut & Run (CnR) of mutant *Inv(V)* E13.5
937 GT. The upper track shows the orientations of the CTCF motives (red and blue arrowheads).
938 The black arrow indicates the major CTCF peak on island V. **B)** 4C-seq profiles (average of
939 two biological replicates) of wildtype and mutant *Del(V)* E13.5 GTs. The positions of the
940 *Hoxd13* (upper tracks) and island IV (lower track) viewpoints are shown with a gray line. The
941 profiles are displayed as overlays of wildtype (blue) and *Del(V)* (red). The red arrow shows the
942 deleted region and the black arrow points to the *Hoxd13* region. **C)** 4C-seq profiles (average
943 of two biological replicates) of wildtype and mutant *Inv(V)* homozygous E13.5 GTs.
944 Viewpoints are highlighted by a gray line. The profiles are shown as overlays of wildtype (blue)
945 and *Inv(V)* (red). The red arrow shows the inverted region and the black arrows indicates the
946 loss of contacts between island IV and the *Hoxd13* region in the *Inv(V)* sample. Percentages in
947 blue (wildtype) and red (*Inv(V)*) represent the proportion of the sums of interactions centromeric

948 or telomeric to island V. (coordinates (mm10) for the quantifications: centromeric:
949 chr2:74015789-74276083; telomeric chr2:74332870-74671433). Coordinates (mm10):
950 chr2:73815520-74792376

951

952 **Figure 8: HOX13 protein binding in C-DOM. A)** HOX13 CnR profiles using E10.5 CR cells
953 (red) and GT cells at E13.5 (Blue). The blue box represents the *HoxD* cluster and gray boxes
954 are non-*Hox* genes. The profile encompasses 4Mb and highlights the enrichment of HOX13
955 binding on both C-DOM and T-DOM *HoxD* regulatory landscapes. Coordinates (mm10): chr2:
956 72760109-76760109. **B)** ATAC-seq and HOX13 CnR profiles of E10.5 CR cells (red) and
957 E13.5 GT cells (Blue). Close-up view of C-DOM and the *HoxD* cluster (coordinates in mm10:
958 chr2:73815520-74792376). The arrows indicate that although the Prox enhancer is bound by
959 HOX13 in the CR at E10.5, the chromatin is not yet accessible at this element.

960

961 MATERIAL AND METHODS

962

963 Mouse strains and genotyping

964 Genotyping of all alleles was done by PCR. Mouse tissue biopsies were lysed for 15'
965 at 95°C, 800rpm, in lysis buffer (50mM NaOH, 0.2mM EDTA). For all genotyping reactions
966 PCR was performed with a standardized cycling protocol (1x(94°3'), 2x(94°1' .62°1',72°1'),
967 30x(94°30''.62°30'',72°30''), 1x(72°10')). The primers used to genotype the *Del(rell-rel5)*,
968 *Del(rel5-SB)*, and *Del(SB-Atf2)* alleles can be found in (Montavon et al., 2011). Primers used
969 to genotype the remaining alleles can be found in Table supplement 1.

970

971 CRISPR-Cas9

972 With the exception of the *Del(rell-rel5)*, *Del(rel5-SB)*, and *Del(SB-Atf2)* alleles
973 (Montavon et al., 2011), all mouse strains carrying deletions or inversions of the different
974 regulatory regions were generated using CRISPR–Cas9 genome editing technology. Single
975 guide RNAs (sgRNAs) were designed flanking the genomic regions of interest (5' and 3' to
976 the regions of interest) using the crispr.mit.edu web tool (from the Zang laboratory) for the
977 *Del(V)*, *Inv(V)*, and *Del(GT2)* alleles, or CCTop (Stemmer et al., 2015) for the *Del(III)*,
978 *Del(Pox)*, and *Del(IV-SB)* alleles (Table supplement 2). All sgRNAs were cloned, as
979 recommended in (Cong et al., 2013), into the BbsI site of the pX330:hSpCas9 (Addgene ID
980 42230) vector. The mouse strains *Del(V)*, *Inv(V)*, and *Del(GT2)* were produced by pronuclear

981 injection (Mashiko et al., 2013) of a mix of the two appropriate sgRNAs cloned into the
982 pX330:hSpCas9 vector (sgRNA:pX330:hSpCas9) (25 ng/μl each). The mouse strains *Del(IV-*
983 *SB)*, *Del(IV)*, *Del(III)*, and *Del(Prox)* were produced by electroporation (Hashimoto and
984 Takemoto, 2015) using a mix containing Cas9 mRNA (final concentration of 400ng/μl) and
985 two sgRNAs (300ng/μl each) in Opti-MEM 1x injection buffer. PCR based genotyping was
986 carried out with primers designed on both sides of sgRNAs targets, with an approximate
987 distance of 150-300bp from the cutting site (Table supplement 1). Sanger sequence of positive
988 PCR bands was used to identify and confirm the deletion or inversion breakpoints of the F0
989 funder animals (figure supplement 5).

990

991 **Transgenic analysis**

992 All mouse fosmid clones were obtained from BACPAC Resources Center
993 (<https://bacpacresources.org>) (Table supplement 3). Their integrity was verified by Sanger
994 sequence and restriction enzyme fingerprinting. The fosmids were introduced in EL250 cells
995 (Lee et al., 2001) and targeted, by ET-recombineering, with a construct containing a *PI-SceI*
996 restriction site, a *βglobin::LacZ* reporter gene with a FRT-flanked kanamycin selection marker,
997 and flanked by 50 bp-long homology arms. The targeting constructs were produced by PCR
998 amplification using the primers indicated in Table supplement 4 to introduce the homology
999 arms. The W11-D5 was shortened to remove the sequences that corresponded to island-IV. The
1000 targeted fosmids were selected at 30°C on LB plates containing chloramphenicol and
1001 kanamycin. The integrity of each modified fosmid was verified by restriction enzyme
1002 fingerprinting, and the correct integration of the *βglobin::LacZ* reporter gene was confirmed
1003 by PCR and Sanger sequence. All fosmids were linearized with *PI-SceI* and micro-injected into
1004 mouse oocytes. Embryos were harvested at E13.5 and stained for β-galactosidase activity
1005 following standard procedures. A minimum of three transgenic animals with consistent staining
1006 were obtained per construct. The transgenic mouse embryos for either the Prox or GT2 were
1007 obtained as described in (Gonzalez et al., 2007; Lonfat et al., 2014). Embryos were stained
1008 using standard procedures. Whole embryos (E13.5) were fixed in 4% paraformaldehyde at
1009 4°C for 35 min, stained in a solution containing 1 mg/ml X-gal at 37°C overnight, washed
1010 in PBS, imaged, and stored in 4% paraformaldehyde.

1011

1012 **Whole-mount *in situ* hybridization**

1013 Whole-mount *in situ* hybridization (WISH) was performed according to (Woltering et
1014 al., 2014). Briefly, embryos were dissected in PBS and fixed overnight in 4%
1015 paraformaldehyde (PFA), washed in PBS, dehydrated, and stored in 100% methanol at -20°C.
1016 Rehydration was performed by a series of methanol/TBS-T washes, followed by a short
1017 digestion of Proteinase K, and re-fixation in 4% PFA. Pre-hybridization, hybridization, and
1018 post-hybridization steps were carried out at 67°C. For all genotypes, both mutant and control
1019 wildtype (E12.5) littermate embryos were processed in parallel to maintain identical conditions
1020 throughout the WISH procedure. DIG-labeled probes for *in situ* hybridizations were produced
1021 by *in vitro* transcription (Promega) and detection was carried out using an alkaline phosphatase
1022 conjugated anti-digoxigenin antibody (Roche). *Hoxd13* and *Evx2* WISH probes were
1023 previously described (Dolle et al., 1991a; Herault et al., 1996). For detection the chromogenic
1024 substrates NBT/BCIP or BM-purple were used.

1025

1026 **RT-qPCR**

1027 Before processing, all tissues were stored at -80°C in RNAlater stabilization reagent
1028 (Invitrogen). RNA was extracted from single micro-dissected GT (E12.5) or single cloaca
1029 region (CR) (E10.5), using Qiagen Tissue Lyser and RNeasy Plus kit (Qiagen), according to
1030 the manufacturer's instructions. RNA was reverse transcribed using Superscript III (Invitrogen)
1031 or Superscript IV (Invitrogen) and random hexamers. qPCR was performed on a CFX96 real-
1032 time system (BioRad) using GoTaq qPCR Master Mix (Promega). Primers were previously
1033 described in (Montavon et al., 2008). Three technical replicates were used per biological
1034 replicate. Relative gene expression levels were calculated by the $2^{-\Delta Ct}$ method using a reference
1035 gene. *Tubβ* was chosen as internal control and the mean of wildtype control samples was set
1036 as reference to calculate the ratio between the different samples. Graphical representation and
1037 statistical analysis were performed with GraphPad Prism 7.

1038

1039 **4C-seq**

1040 Circular chromosome conformation capture (4C-seq) was performed as described in
1041 (Noordermeer et al., 2011). Briefly, tissues (20-40 GT or 40 CR) were isolated in PBS
1042 supplemented with 10% Fetal Calf Serum and dissociated to single cell by collagenase
1043 treatment. Samples were fixed in 2% formaldehyde, lysed, and stored at -80°C. Pools of
1044 between 20-40 GT or 40 CR were primarily digested with NlaIII (NEB, R0125L) followed by
1045 ligation under diluted conditions. After decrosslinking and DNA purification DpnII (NEB,

1046 R0543M) was used for the second restriction. All ligation steps were performed using highly
1047 concentrated T4 DNA ligase (Promega, M1794). For each viewpoint approximately 1µg of
1048 DNA was amplified by using 12 individual PCR reactions. Libraries were constructed with
1049 inverse primers for different viewpoints (see Table supplement 5) containing Illumina Solexa
1050 adapter sequences and sequenced on an Illumina HiSeq 2500 sequencer, as single-end reads
1051 (read length 100 base pairs or 80 base pairs). In some samples 4-bp barcodes were added
1052 between the adapter and each specific viewpoint to allow sample multiplexing.

1053 4C-seq reads were demultiplexed, mapped on GRCm38/mm10 mouse assembly, and
1054 analyzed using the 4C-seq pipeline of the Bioinformatics and Biostatistics Core Facility (BBCF)
1055 HTSstation (<http://htsstation.epfl.ch>) (David et al., 2014) or using a local version of it using
1056 the facilities of the Scientific IT and Application Support Center of EPFL. Profiles were
1057 normalized to a 5Mb region surrounding the *HoxD* cluster and smoothed using a window
1058 size of 11 fragments. C-DOM quantifications on Figure 2 were done by dividing the sum of
1059 the scores in the C-DOM (chr2:73921943–74648943) by the sum of the scores that fall in a
1060 non-interacting region of the T-DOM (chr2:75166258-75571741) (background local
1061 normalization). Signals falling either centromeric or telomeric to island V (in Figure 7 and
1062 Figure 7–figure supplement 4) were assessed by calculating the sum of the scores in the region
1063 of interest normalized by the sum of the scores in both regions (coordinates (mm10) for the
1064 quantifications: centromeric: chr2:74015789-74276083; telomeric chr2:74332870-74671433).
1065 Quantifications of the interactions established with the cis-regulatory elements in Figure 2–
1066 figure supplement 2 were calculated as a percentage of the sum of the scores of each element
1067 using the mESC sample as a reference.

1068

1069 **ChIP-seq**

1070 Micro-dissected 35-40 GT or 70 CR were crosslinked in 1% formaldehyde/PBS for 20
1071 min and stored at -80°C until further processing. Chromatin was sheared using a water-bath
1072 sonicator (Covaris E220 evolution ultra-sonicator). Immunoprecipitation was done using the
1073 following antibodies, anti-CTCF (Active Motif, 61311), anti- H3K27ac (Abcam, ab4729), and
1074 H3K27me3 (Merck Millipore, 07-449). Libraries were prepared using the TruSeq protocol,
1075 and sequenced on the Illumina HiSeq system (100bp single-end reads) according to
1076 manufactures instructions.

1077 ChIP-seq reads processing was done on the Duboule lab local Galaxy server (Afgan et al.,
1078 2016). Adapters and bad-quality bases were removed with Cutadapt version 1.16 (Martin,

1079 2011) (options -m 15 -q 30 -a GATCGGAAGAGCACACGTCTGAACTCCAGTCAC).
1080 Reads were mapped to the mouse genome (mm10) using Bowtie2 (v2.3.4.1) (Langmead and
1081 Salzberg, 2012), with standard settings. The coverage was obtained as the output of MACS2
1082 (v2.1.1.20160309) (Zhang et al., 2008). Peak calling in Figure 5 was done using MACS2
1083 (v2.1.0.20160309) call peak (--gsize 1870000000) using the corresponding input data as
1084 control BAM (-c). CTCF motif orientation was assessed using the CTCFBSDB 2.0 database
1085 (Ziebarth et al., 2012), with EMBL_M1 identified motifs.

1086

1087 **ATAC-seq**

1088 ATAC-seq was performed as described in (Buenrostro et al., 2013). Briefly, micro-
1089 dissected tissues (a pool of 2 GT or 2-3 CR) were isolated in PBS supplemented with 10% Fetal
1090 Calf Serum and dissociated to single cell by collagenase treatment. After isolation, 50,000 cells
1091 were lysed in 50 μ l of lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl₂
1092 and 0.1% IGEPAL CA-630), nuclei were carefully resuspended in 50 μ l transposition
1093 reaction mix (25 μ l TD buffer, 2.5 μ l Tn5 transposase and 22.5 μ l nuclease-free water) and
1094 incubated at 37 °C for 30min. DNA was isolated with a MinElute DNA Purification Kit
1095 (Qiagen). Library amplification was performed by PCR (10 to 12 cycles) using NEBNext
1096 High-Fidelity 2x PCR Master Mix (NEB, M0541S). Library quality was checked on a
1097 fragment analyzer, and paired-end sequencing was performed on an Illumina NextSeq 500
1098 instrument (read length 2 \times 37 base pairs).

1099 ATAC-seq reads processing was done on the Duboule lab local Galaxy server (Afgan
1100 et al., 2016). Reads were mapped to the mouse genome (mm10) using Bowtie2 (v2.3.4.1)
1101 (Langmead and Salzberg, 2012), (-I 0 -X 2000 --fr --dovetail --very-sensitive-local). Reads
1102 with mapping quality below 30, mapping to mitochondria, or not properly paired were
1103 removed from the analysis. PCR duplicates were filtered using Picard (v1.56.0). Peak calling
1104 was done using MACS2 (v2.1.0.20151222) call peak (--nomodel --shift -100 --extsize 200 --
1105 call-summits). The coverage was done using the center of the Tn5 insertion and extended on
1106 both sides by 20bp (script developed by L. Lopez-Delisle). When indicated, coverage profiles
1107 represent an average of the replicates, this was done by dividing each replicate by the number
1108 of million reads that fall within peaks in each sample (for normalization) and calculating the
1109 average coverage.

1110

1111 **RNA-seq**

1112 Micro-dissected GT from different embryonic stages were individual stored at -80°C
1113 in RNAlater stabilization reagent (Ambion) before further sample processing. Total RNA was
1114 extracted from tissues using Qiagen RNeasy Plus Micro Kit (Qiagen) after disruption and
1115 homogenization. RNA quality was assessed using an Agilent 2100 Bioanalyser. Only samples
1116 with high RNA integrity number were used. Sequencing libraries were prepared according to
1117 TruSeq Stranded mRNA Illumina protocol, with polyA selection. RNA-seq libraries were
1118 sequenced on an Illumina HiSeq 2500 sequencer, as single-end reads (read length 100 base
1119 pairs).

1120 Raw RNA-seq reads were aligned on the mouse mm10 genome assembly using TopHat
1121 2.0.9 (Yates et al., 2016). Gene expression computations were performed using uniquely
1122 mapping reads extracted from TopHat alignments and genomic annotations from filtered gtf
1123 from Ensembl release 82 (Kim et al., 2013) as discribed in (Amândio et al., 2016). FPKM
1124 (fragments per kilo- base per million mapped fragments) expression levels for each gene were
1125 calculated using Cufflinks (Roberts et al., 2011).

1126

1127 **Cut & Run**

1128 Cut & Run (Schmid et al., 2004; Skene and Henikoff, 2017) was performed as
1129 described in (Meers et al., 2019; Skene et al., 2018). Briefly, micro-dissected tissues (a set of
1130 8 to 10 GT or CR) were isolated in PBS supplemented with 10% fetal calf serum and
1131 dissociated to single cell by collagenase treatment. After isolation, 500000 cells were washed
1132 and bond to concanavalin A-coated magnetic beads and permeabilized with wash buffer (20
1133 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM spermidine, and Roche Complete protein
1134 inhibitor) containing 0.02% digitonin. Bonded cells were incubated with primary antibody
1135 (anti-HOXD13, AbCam ab19866; anti-CTCF, Active Motif, 6131) for 2h at room temperature.
1136 After washes the samples were incubated with Protein A-MNase (pA-MN) for 1 hour at 4°C,
1137 then washed twice more with Wash Buffer. Samples were resuspended in low-salt rinse buffer
1138 (20 mM HEPES, pH7.5, 0.5 mM spermidine, and 0.125% Digitonin) and chilled to 0°C and
1139 the liquid was removed on a magnet stand. Ice-cold calcium incubation buffer (3.5 mM HEPES
1140 pH 7.5, 10 mM CaCl₂, 0.05% Digitonin) was added and samples were incubated on an ice-cold
1141 block for 30 min. STOP buffer (270 mM NaCl, 20 mM EDTA, 4 mM EGTA ,0.02% Digitonin,
1142 50 µg glycogen, 50 µg RNase A) was added and samples were incubated at 37°C for 30 min,
1143 replaced on a magnet stand and the liquid was removed to a fresh tube. DNA was extracted by
1144 Phenol-Chloroform extraction and ethanol precipitation. Libraries were prepared as described
1145 in (Skene et al., 2018). Library quality was checked on a fragment analyzer, and paired-end

1146 sequencing was performed on an Illumina NextSeq 500 instrument (read length 2×37 base
1147 pairs).

1148 Cut & Run reads processing was done on the Duboule lab local Galaxy server (Afgan
1149 et al., 2016). Reads were mapped to the mouse genome (mm10) using Bowtie2 (v2.3.4.1)
1150 (Langmead and Salzberg, 2012), (-I 0 -X 1000 --fr --dovetail --very-sensitive). Reads with
1151 mapping quality below 30, mapping to mitochondria, or not properly paired were removed
1152 from the analysis. The output BAM file was converted to BED using bamtobed bedtools
1153 v2.18.2 (Quinlan, 2014). The coverage was obtained as the output of MACS2
1154 (v2.1.1.20160309) (Zhang et al., 2008) (--format BED --keep-dup 1 --bdg --nomodel --extsize
1155 200 --shift -100).

1156

1157 **Ethics approval**

1158 All experiments were performed in agreement with the Swiss law on animal protection (LPA),
1159 under license No GE 81/14 (to DD).

1160 **Data availability**

1161 All raw and processed RNA-seq, 4C-seq, ChIP-seq, Cut & Run, and ATAC-seq
1162 datasets are available in the Gene Expression Omnibus (GEO) repository under accession
1163 number GSE138514.

1164

1165 **Competing interests**

1166 The authors declare that they have no competing interests.

1167

1168 **Funding**

1169 C.C.B is supported by the National Institute of Child Health & Human Development of the
1170 National Institutes of Health (NIH NICHD F32HD0935). This work was supported by funds
1171 from the École Polytechnique Fédérale (EPFL, Lausanne), the University of Geneva, the Swiss
1172 National Research Fund (No. 310030B_138662) and the European Research Council grants
1173 *SystemHox* (No 232790) and *RegulHox* (No 588029) (to D.D.). Funding bodies had no role in
1174 the design of the study and collection, analysis and interpretation of data and in writing the
1175 manuscript.

1176

1177 **Author's contributions**

1178 Design of experiments, RA, CB, BM and DD; Bench work, RA, BM; Computing analysis, RA,
1179 LL-D; Analysis of results, RA, LL-D, DD; Manuscript writing, RA, CB, LL-D and DD;
1180 Funding acquisition, DD, CB. All authors read and approved the final manuscript

1181


1182 **Acknowledgements**

1183 We thank all members of the Duboule laboratories for insightful comments and discussion. We
1184 are grateful to Sandra Gitto and Thi Hanh Nguyen Huynh for their help with mice breeding
1185 and genotyping, as well as Mylène Docquier, Brice Petit and Christelle Barraclough
1186 (University of Geneva) and Bastien Mangeat and the gene expression core facility (GECF,
1187 EPFL Lausanne) for DNA sequencing. We also thank Marion Leleu for her help with data
1188 analysis.


1189

1190


Amândio et al.
Figure 1




Amândio et al.
Figure 2




Amândio et al.
Figure 3




Amândio et al.
Figure 4




Amândio et al.
Figure 5



Amândio et al.
Figure 6



Amândio et al.
Figure 7



Amândio *et al.*
Figure 8

